Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

MRSN

Mersana Therapeutics (MRSN)

Mersana Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MRSN
DateHeureSourceTitreSymboleSociété
22/05/202414h00GlobeNewswire Inc.Mersana Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:MRSNMersana Therapeutics Inc
17/05/202414h26Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MRSNMersana Therapeutics Inc
10/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MRSNMersana Therapeutics Inc
09/05/202423h06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MRSNMersana Therapeutics Inc
09/05/202415h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRSNMersana Therapeutics Inc
09/05/202413h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRSNMersana Therapeutics Inc
09/05/202412h59GlobeNewswire Inc.Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial ResultsNASDAQ:MRSNMersana Therapeutics Inc
03/05/202422h30GlobeNewswire Inc.Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MRSNMersana Therapeutics Inc
02/05/202414h00GlobeNewswire Inc.Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024NASDAQ:MRSNMersana Therapeutics Inc
28/02/202422h05Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:MRSNMersana Therapeutics Inc
28/02/202414h49Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MRSNMersana Therapeutics Inc
28/02/202414h43Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:MRSNMersana Therapeutics Inc
28/02/202413h00GlobeNewswire Inc.Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:MRSNMersana Therapeutics Inc
21/02/202414h00GlobeNewswire Inc.Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024NASDAQ:MRSNMersana Therapeutics Inc
16/02/202422h30Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:MRSNMersana Therapeutics Inc
15/02/202402h56Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRSNMersana Therapeutics Inc
01/02/202414h00GlobeNewswire Inc.Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology ConferenceNASDAQ:MRSNMersana Therapeutics Inc
17/01/202423h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRSNMersana Therapeutics Inc
17/01/202403h14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MRSNMersana Therapeutics Inc
12/01/202422h42Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MRSNMersana Therapeutics Inc
05/01/202414h01GlobeNewswire Inc.Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MRSNMersana Therapeutics Inc
07/11/202313h00GlobeNewswire Inc.Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial ResultsNASDAQ:MRSNMersana Therapeutics Inc
31/10/202321h30GlobeNewswire Inc.Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023NASDAQ:MRSNMersana Therapeutics Inc
31/10/202317h59Dow Jones NewsMersana Therapeutics Shares Rise 8% After FDA Lifts Clinical Hold for Cancer TreatmentNASDAQ:MRSNMersana Therapeutics Inc
31/10/202314h07Dow Jones NewsMersana Says FDA Lifts Clinical Hold on Gastric-Cancer Treatment Phase I TrialNASDAQ:MRSNMersana Therapeutics Inc
31/10/202313h00GlobeNewswire Inc.Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056NASDAQ:MRSNMersana Therapeutics Inc
07/09/202323h46Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRSNMersana Therapeutics Inc
06/09/202313h00GlobeNewswire Inc.Mersana Therapeutics Announces Changes in LeadershipNASDAQ:MRSNMersana Therapeutics Inc
08/08/202314h00GlobeNewswire Inc.Mersana Therapeutics Announces Second Quarter 2023 Financial ResultsNASDAQ:MRSNMersana Therapeutics Inc
27/07/202313h06GlobeNewswire Inc.Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic ReprioritizationNASDAQ:MRSNMersana Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MRSN

Dernières Valeurs Consultées

Delayed Upgrade Clock